Sequencing Agents in Prostate Cancer

Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, discusses sequencing agents in prostate cancer.

Clinical Pearls:

• Agents such as enzalutamide, abiraterone, and radium-223, are now FDA-approved and proven to improve survival
• Physicians sequence these agents based on approval parameters from the FDA, but this may not be the best way
• Physicians need to understand more about the biology and cross-resistance patterns of these agents and how to integrate rational combinations with limited toxicities in order to improve sequencing techniques